ROLE OF MONTELUKAST ON PERENNIAL ALLERGIC RHINITIS & ASSOCIATED SLEEP DISTURBANC

孟鲁司特对常年性过敏性鼻炎的作用

• 批准号: 7625744
• 负责人: Timothy John Craig
• 金额: $ 2万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625744
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Drowsiness; Fatigue; Funding; Grant; Institution; Leukotriene Antagonists; Nose; Perennial Allergic Rhinitis; Research; Research Personnel; Resources; Role; Sleep; Sleep Fragmentations; Source; United States National Institutes of Health; montelukast

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypothesis for this study is that a leukotriene receptor antagonist (LRA), Montelukast, will decrease nasal congestion leading to increased patency of the nose and a decrease in nighttime sleep fragmentation. This decrease in sleep fragmentation will reduce daytime somnolence and fatigue.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的假设是，一种白三烯受体拮抗剂（LRA），孟鲁司特，将减少鼻塞，导致增加鼻子的通畅性和减少夜间睡眠碎片。 这种睡眠碎片的减少将减少白天的嗜睡和疲劳。